文献速递妇科

阿替利珠单抗在晚期/复发性卵巢癌和子宫癌中的安全性、临床活性及生物标志物评估:一项Ⅰ期研究

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
PubMed 文献 · Gynecol Oncol · 2019-06-14

该Ⅰ期多中心首次人体开放标签剂量递增/扩展试验评估了阿替利珠单抗单药在复发性上皮性卵巢癌和子宫癌患者中的安全性、耐受性及抗肿瘤活性。卵巢癌和子宫癌队列分别入组12例和15例患者,治疗相关不良事件大多为1-2级,未报告治疗相关4级及以上不良事件;两个队列各有2例患者观察到初步抗肿瘤活性,且缓解持续时间较长。结论认为阿替利珠单抗单药耐受性良好,可能具有临床活性,值得进一步研究。

要点

  • 卵巢癌队列12例中10例(83%)肿瘤浸润免疫细胞PD-L1≥5%,子宫癌队列15例中5例(33%)PD-L1≥5%。
  • 治疗相关不良事件大多为1-2级,未报告治疗相关4级及以上不良事件,未发现新的安全性信号。
  • 卵巢癌和子宫癌队列各有2例患者观察到初步抗肿瘤活性,缓解持续时间较长。

核心结论

  • 阿替利珠单抗单药在复发性上皮性卵巢癌或子宫癌患者中耐受性良好,可能具有临床活性,值得进一步研究。

研究设计与样本

  • Ⅰ期、多中心、首次人体、开放标签、剂量递增/扩展临床试验,评估阿替利珠单抗单药在复发性上皮性卵巢癌或子宫癌患者队列中的安全性和耐受性。
  • 卵巢癌队列入组12例患者,子宫癌队列入组15例患者。
  • 主要目标为评估阿替利珠单抗单药的安全性和耐受性,抗肿瘤活性和潜在生物标志物的初步评估分别为次要目标和探索性目标。
  • 试验注册号:ClinicalTrials.gov NCT01375842。

主要发现

  • 卵巢癌队列12例中10例(83%)肿瘤浸润免疫细胞PD-L1≥5%,子宫癌队列15例中5例(33%)PD-L1≥5%。
  • 阿替利珠单抗总体耐受性良好,未发现新的安全性信号;两个队列的安全性特征与阿替利珠单抗单药已知特征一致。
  • 治疗相关不良事件大多为1-2级,未报告治疗相关4级及以上不良事件。
  • 卵巢癌队列有2例患者观察到初步抗肿瘤活性,缓解持续时间分别为8.1个月和30.6+个月;子宫癌队列有2例患者观察到初步抗肿瘤活性,缓解持续时间分别为7.3个月和16.6+个月。
  • 子宫癌队列的缓解者中观察到高度微卫星不稳定和肿瘤突变负荷。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with advanced/recurrent epithelial ovarian and uterine cancers have limited treatment options beyond platinum chemotherapy. Both tumor types can express programmed death-ligand 1 (PD-L1), providing a potential therapeutic target for these patients. Here we present data from the ovarian and uterine cancer cohorts of the Phase I atezolizumab monotherapy study (PCD4989g). METHODS: This Phase I, multi-center, first-in-human, open-label, dose-escalation/expansion clinical trial investigated single-agent atezolizumab in cohorts of patients with recurrent epithelial ovarian or uterine cancer. The primary objective was to evaluate the safety and tolerability of single-agent atezolizumab. Anti-tumor activity and preliminary assessment of potential biomarkers were evaluated as secondary and exploratory objectives, respectively. RESULTS: The ovarian and uterine cancer cohorts enrolled 12 and 15 patients, respectively (10 [83%] and 5 [33%], respectively, had PD-L1 ≥ 5% on tumor-infiltrating immune cells). Atezolizumab was generally well tolerated with no new safety signals identified. The safety profiles in both cohorts were consistent with the known profile of atezolizumab monotherapy. Treatment-related adverse events (AEs) were mostly Grade ≤ 2, with no treatment-related Grade ≥ 4 AEs reported. Preliminary anti-tumor activity, with long durations of response, was observed in 2 patients from each cohort (ovarian cancer, 8.1 and 30.6+ months; uterine cancer, 7.3 and 16.6+ months). High microsatellite instability and tumor mutational burden were noted in the responders from the uterine cancer cohort. CONCLUSIONS: Atezolizumab monotherapy was well tolerated in patients with epithelial ovarian or uterine cancer and may have clinical activity warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01375842.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019. PMID: 31204078. doi:10.1016/j.ygyno.2019.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。